2cureX (2CUREX) H2 2025 earnings summary

Executive summary

• Continued execution under a clarified group structure, focusing on commercial access and patient engagement in precision oncology.

• Strategic partnership with 2cureX A/S for development and regulatory approval of IndiTreat; commercial model aligned for hospital installations in 2026.

• Entered a non-binding LOI with PreComb Therapeutics AG for potential collaboration in precision oncology.

• First direct-to-patient IndiTreat test conducted, marking a milestone in patient engagement.

• Proceeds from the sale of 2cureX A/S (MSEK 5.6) partially distributed to shareholders, with the remainder pending annual report review.

Financial highlights

• Net sales for H2 2025 were 0 KSEK; other operating income was 3 KSEK.

• Operating profit for H2 2025 was -644 KSEK; profit before tax was -659 KSEK.

• Cash and bank balances stood at 2,096 KSEK as of December 31, 2025.

• Equity ratio as of December 31, 2025 was -1.7%.

• Earnings per share for H2 2025 was -0.03 SEK.

Outlook and guidance

• Focus on refining and executing the commercial access model and supporting patient engagement aligned with hospital-based IndiTreat deployment.

• Continued strict capital discipline and close collaboration with strategic partners.

• Further updates to be provided as progress continues.